Eating fibre, replacing gas stoves and regular ejaculation are just some of the ways cancer experts are reducing their risk ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Fatigue assessment when treatment is started may be an early clinical marker of adverse event risk, the researchers suggested ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Patients’ fatigue levels before starting systemic cancer treatment predict their risk for severe or fatal side effects.

The prostate is a gland wrapped around the urethra. Its main function is to produce part of the semen ejaculated at male ...

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...